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health status measure for low back pain (LBP). It is not preference-
based, and there are currently no established algorithms for mapping
between the RMQ and preference-based health-related quality-of-life
measures. Using data from randomized controlled trials of treatment
for LBP, we sought to develop algorithms for mapping between RMQ
scores and health utilities derived using either the EuroQol ﬁve-
dimensional questionnaire (EQ-5D) or the six-dimensional health
state short form (derived from Medical Outcomes Study 36-Item
Short-Form Health Survey) (SF-6D). Methods: This study is based on
data from the Back Skills Training Trial in which data were collected
from 701 patients at baseline and subsequently at 3, 6, and 12 months
postrandomization using a range of outcome measures, including the
RMQ, the EQ-5D, and the Short Form 12 item Health Survey (SF-12)
(from which SF-6D utilities can be derived). We used baseline trial
data to estimate models using both direct and response mapping
approaches to predict EQ-5D and SF-6D health utilities and dimension
responses. A multistage model selection process was used to assess
the predictive accuracy of the models. We then explored different
techniques and mapping models that made use of repeated follow-up
observations in the data. The estimated mapping algorithms wereee front matter Copyright & 2014, International S
r Inc.
1016/j.jval.2014.07.001
@warwick.ac.uk.
ondence to: Kamran A. Khan, Warwick Clinical Tr
ick, Coventry CV4 7AL, UK.validated using external data from the UK Back Pain Exercise and
Manipulation trial. Results: A number of models were developed that
accurately predict health utilities in this context. The best performing
model for RMQ to EQ-5D mapping was a beta regression with Bayesian
quasi-likelihood estimation that included 24 dummy variables for
RMQ responses, age, and sex as covariates (mean squared error
0.0380) based on repeated data. The model selected for RMQ to SF-
6D mapping was a ﬁnite mixture model that included the overall RMQ
score, age, sex, RMQ score squared, age squared, and an interaction
term for age and RMQ score as covariates (mean squared error 0.0114)
based on repeated data. Conclusions: It is possible to reasonably
predict EQ-5D and SF-6D health utilities from RMQ scores and
responses using regression methods. Our regression equations pro-
vide an empirical basis for estimating health utilities when EQ-5D or
SF-6D data are not available. They can be used to inform future
economic evaluations of interventions targeting LBP.
Keywords: cross-walking, EQ-5D, health-related quality of life, health
utilities, low back pain, LBP, mapping, RMQ, SF-6D.
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Low back pain (LBP) is a major public health problem in Western
industrialized societies. In the United Kingdom, the annual
prevalence of LBP is approximately 37% and LBP is so common
that it affects almost everyone at some point during his or her
lifetime [1,2]. The direct health care costs associated with LBP in
1998 in the United Kingdom were £1628 million (1998 prices); the
majority of this expenditure fell on physiotherapy services and
general practice. During the years 1994 and 1995, 116 million
production days were estimated to have been lost in the United
Kingdom because of LBP, resulting in an estimated £10,668
million (1998 prices) in lost productivity and informal care costs
[1,3].To treat individuals with LBP, new treatments and therapies
are being developed and clinical trials have been conducted to
test the efﬁcacy of these new interventions [4–6]. Outcome
measures within these trials have tended to include disease-
speciﬁc and generic health-related quality-of-life (HRQOL) instru-
ments. The Roland Morris Questionnaire (RMQ) is one of the most
extensively used and recognized disease-speciﬁc outcome meas-
ures in back pain studies [7]. It is not preference-based, however,
and cannot be used for the estimation of quality-adjusted life-
years. Many decision makers, such as the National Institute for
Health and Care Excellence in England and Wales, recommend
the use of the quality-adjusted life-years (a preference-based
measure of health outcome that combines length of life and
health-related quality of life in a single metric) as a standardociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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EuroQol ﬁve-dimensional questionnaire (EQ-5D) as the integral
preference-based measure of HRQOL [8]. In LBP studies in which
the RMQ but no preference-based measure is collected, a poten-
tial solution is to apply a mapping (or “crosswalk”) function to
convert RMQ scores into preference-based (or utility) values.
“Mapping” involves the development and use of an algorithm
(or algorithms) to predict health-state utility values using data on
other indicators or measures of health [9]. The algorithm(s) can
be applied to data from clinical trials, observational studies, or
economic models containing the source predictive measure(s) to
predict utility values even though the target preference-based
measure was not included in the original source study. The
predicted utility values can then be analyzed using standard
methods for trial-based analyses or summarized for each health
state within an economic model [9]. The aim of this study was to
examine the relationship between the RMQ and generic
preference-based measures collected as part of clinical trials
and to develop well-ﬁtting mapping algorithms between them.
These algorithms can be used to derive utilities in subsequent
analyses, such as economic evaluations reliant on data sets that
include only RMQ information. In addition, we go on to explore
different techniques and mapping models that exploit the infor-
mation available from repeated observations in our data sets.Methods
Data
The primary data for this study were drawn from the Back Skills
Training Trial (BeST) [4]. BeST was a pragmatic, multicenter,
randomized controlled trial that recruited 701 participants from
56 general practices in seven regions across England. Individuals
were eligible for inclusion if they were aged 18 years or older, had
at least moderately troublesome subacute or chronic LBP of a
minimum of 6 weeks, and had consulted for LBP in primary care
within the preceding 6 months. The main aim of BeST was to
estimate the clinical effectiveness of two interventions—active
management and active management combined with a cognitive
behavioral approach—in reducing the disability associated with
LBP. The outcome measures in BeST included the RMQ [10], the
EQ-5D [11], and the Short Form 12 item Health Survey version 2
(SF-12(v2)) [12], and these were collected at baseline and at 3, 6,
and 12 months postrandomization.
External validation of the algorithms was performed using
data from the UK Back Pain Exercise and Manipulation (UK BEAM)
trial [13]. The UK BEAM trial recruited and randomized 1334
participants to one of four interventions: manipulation, exercise,
manipulation combined with exercise, or best care in general
practice. Among other criteria, individuals were eligible for
inclusion if they were aged between 18 and 65 years and had a
score of four or more on the RMQ on the day of randomization.
The main aim of this trial was to assess the effectiveness of
adding these interventions to best care in general practice
settings. The outcome measures in the UK BEAM trial included
the RMQ, the EQ-5D, and the Medical Outcomes Study 36-Item
Short-Form Health Survey, version 2 (SF-36(v2)) [14], and these
were collected at baseline and at 1, 3, and 12 months
postrandomization.
All participants within each trial were included in the relevant
analyses regardless of trial allocation.
Outcome Measures
The RMQ was originally derived from the Sickness Impact Proﬁle
[10] and contains 24 items relating to a range of functionscommonly affected by LBP and disability. Completion of each
item requires a binary “yes”/“no” response. The total number of
positive responses is summed to form a score (out of 24), and a
low score is associated with less disability.The EQ-5D [11] is the
most widely used generic preference-based measure of health
outcome [15]. It consists of two principal measurement compo-
nents, a descriptive system and a visual analogue scale. This
study concentrates on mapping onto information provided by the
descriptive system, which is composed of ﬁve dimensions of
health: mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression. Each dimension is assessed by a single
question on a three-point ordinal scale (no problems, some or
moderate problems, severe or extreme problems). This generates
a total number of 243 (35) possible EQ-5D health states. In the
United Kingdom, utility valuations for all 243 EQ-5D health states
are commonly based on the York A1 tariff set derived from a
survey of the UK population (n ¼ 3337), which used the time
trade-off valuation method to estimate utility scores for a subset
of 45 EQ-5D health states and a multivariate model to estimate
values for the remainder of the EQ-5D health states [16]. Utility
valuations in the York A1 tariff set range from no problems on
any of the ﬁve dimensions in the EQ-5D descriptive system (value
¼ 1.0) to severe or extreme impairment on all ﬁve dimensions
(value ¼ 0.594). Alternative tariffs for the EQ-5D have been
developed for other countries [17].
The six-dimensional health state short form (derived from the
SF-36) (SF-6D) [18] is a preference-based instrument derived from
the SF-36 [14], a widely used instrument that measures health-
related quality of life. Like the EQ-5D, the SF-6D consists of a
descriptive system and a valuation of health states. There are two
versions of the SF-6D, one based on the complete 36-item version
of the SF-36 [18] and the other based on its 12-item derivative (SF-
12) [19]. The SF-6D has six dimensions (pain, mental health,
physical functioning, social functioning, role limitations, and
vitality), and each dimension has between three and six levels,
depending on the response choice categories of the original items
from the SF-36. The SF-6D was valued by a representative sample
of 836 members of the UK general population using the standard
gamble valuation method [18]. The SF-6D utilities for both study
and estimation data sets were calculated using the SF-12 con-
verter (for the validation [UK BEAM] data set, responses to the SF-
12 questions were extracted from the SF-36 data).
Statistical Methods
For the ﬁrst stage of our analyses, we developed mapping
algorithms using only baseline trial data and made use of both
direct utility and response mapping approaches to estimate
utility scores based on the RMQ scores. The direct utility
approach makes use of regression equations to predict the values
of one outcome measure (in our case, EQ-5D or SF-6D utilities)
using scores/values from a second measure as regressors (in our
case, RMQ scores). The coefﬁcients of the models can then be
used to carry out the conversion from the starting measure to the
target measure in the required data sets. The estimation techni-
ques used for the direct utility mapping were ordinary least
squares, Tobit regression [20], fractional logistic regression
[21,22], censored least absolute deviations (CLAD) regression
[23,24], generalized linear modeling (GLM) [25], generalized addi-
tive models [26], beta regression (ﬁtted using maximum-
likelihood estimation or quasi-likelihood estimation [QMLE]
methods [27]), and ﬁnite mixture models [28]. To implement
fractional logistic regression, utilities were linearly transformed
to obtain a dependent variable bounded between zero and one.
Then, a GLM model with a binomial family and a logit link was
implemented to predict utility0-1. Finally, predictions were back-
transformed to obtain the usual utility range. Beta regression
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 8 6 – 6 9 5688(maximum-likelihood estimation and QMLE) and mixture models
were ﬁtted via Bayesian Markov chain Monte Carlo. Convergence
of Markov chain Monte Carlo estimates was conﬁrmed using
multiple chains using randomly generated initial values. For
mixture models, we used age, sex, and the RMQ score to estimate
probabilities of component membership because these were the
only variables available for this purpose. For the GLM models, the
modiﬁed Parks test [29] was used to identify the preferred
distributional family on the basis of the lowest chi-square value.
For each prediction model, tests were carried out to identify the
link (including identity, square root, and log) using the Pearson
correlation test [30], the Pregibon link test [31], and the modiﬁed
Hosmer-Lemeshow test [32]. Where all three tests yield non-
signiﬁcant P values, the link function is said to ﬁt well [33].
We then used response mapping to predict responses to the
EQ-5D or SF-6D dimensions as opposed to predicting the sum-
mary utility scores directly [34]. A logistic regression model can
be used to estimate the probabilities that each set of RMQ
responses corresponds to a response level for each EQ-5D or SF-
6D dimension. A multinomial logistic model can be used or an
ordered logistic model if it is believed that responses to EQ-5D or
SF-6D questions are ordered. The models were estimated by
ﬁtting a separate multinomial logistic regression (MLOGIT) model
for each EQ-5D or SF-6D dimension, as described elsewhere [34].
Predictions for the response mapping models were generated
using the expected value method.
For the second stage of the analyses, we reestimated mapping
algorithms for the EQ-5D and SF-6D utility scores on the basis of
RMQ scores using the repeated measurements available in the
BeST data set. This type of longitudinal data can be seen to have a
two-tier structure in which the measurement occasions (level 1
units) are nested within subjects (level 2 units). By analyzing the
results at level 1 and ignoring the multilevel nature of the data,
we risk overlooking the importance of group effects, which, in
turn, can render invalid the model-estimated coefﬁcients. We
adapted all the models used for the baseline data analysis. Two
main methods were used: mixed-effects models and models with
robust standard errors. Random-intercept mixed-effect models
were implemented for linear, beta, and mixture regression
models. We also ﬁtted random coefﬁcient linear regression
models (in which all coefﬁcient values vary between individuals).
Mixed-effect models were created in STATA using the XTMIXED
command and in WinBUGS by deﬁning regression equations for
each individual, and then deﬁning a common distribution for
each intercept across individuals. We also explored the use of
ordinary least squares, GLM, and fractional logistic regression
regression with robust standard errors (equivalent to White’s
standard errors in the presence of heteroskedasticity), which
involves relaxing the assumption of independence of the obser-
vations, grouping the data according to the subject identiﬁer, and
treating only those observations with different subject identiﬁers
as truly independent. Within STATA, this is achieved by using the
cluster command on the subject identiﬁers.
For each of the functional forms applied to baseline or repeated
measurements, three sets of covariates were used to predict EQ-5D
or SF-6D utility scores; the ﬁrst set included the overall RMQ score
and age and sex as covariates (from here on referred to as model 1);
in the second set, the explanatory variables were the overall RMQ
score, age, sex, RMQ score squared, age squared, and an interaction
term for age and RMQ score (from here on referred to as model 2);
and in the third set, the explanatory variables were 24 dummy
variables (24 questions each with two possible responses, “no” used
as reference), indicating whether participants had a particular
response level on the RMQ question, and age and sex (from here
on referred to as model 3). Models were estimated in Stata version
11 (Stata-Corp, College Station, TX), R version 2.01, and WinBUGS
version 1.4.3 [35].Assessing Model Performance
We used a multistage model selection process to shortlist a
number of models:
Step 1: For each regression model, we used the Akaike
information criterion [36] to determine the best-performing
covariate set and eliminate the other two covariate sets. For
those models for which the Akaike information criterion could
not be calculated (CLAD and beta QMLE), algorithms based on
all three covariate sets were selected for inclusion in step 2.
Step 2: For the models selected in step 1, we compared the
mean squared error (MSE) in both estimation and validation
samples. Models were eliminated at this stage if there was
another model with lower MSEs in both data sets. This
comparison was performed separately for models ﬁtted to
the entire estimation data set and those ﬁtted to the baseline
values only, because MSEs are not comparable across these
two data sets.
Step 3: For all remaining models, we calculated validation
data set prediction bias, conditional on the RMQ score. Final
model selection was based on performance across the RMQ
range as well as total MSE in the validation sample. Because
all models were validated using the same data set, we were
able, at this stage, to compare models ﬁtted to the whole
estimation data set with models ﬁtted to baseline data only.
To compare the models further, a number of analyses were
carried out using results from the validation sample. First,
distributions of the predicted and observed utility scores were
examined to see how closely predicted values matched
observed scores [37], and the proportions of predictions
deviating from observed values by less than 0.10 or less than
0.25 were also calculated because these indicate the distribu-
tion of errors and how often the models fail to produce useful
predictions [38]. Finally, the errors were reported across
subsets of the EQ-5D and SF-6D utility score ranges because
this is useful for indicating whether there is systematic bias in
the predictions [9].
Results
Characteristics of Study Population
Table 1 summarizes the descriptive statistics across the different
follow-up points in both the BeST study sample and the UK BEAM
validation sample. Because of the longitudinal nature of the
studies and the collection of follow-up data, there were missing
values at each follow-up point. As a result, the total number of
complete pairs of RMQ and EQ-5D observations, and RMQ and SF-
6D observations, available for estimation at baseline were 678
and 667, respectively, and the corresponding values for repeated
observations were 2193 for the RMQ and the EQ-5D and 2144 for
the RMQ and the SF-6D.
Nearly 60% of the participants in the BeST study population
were women, the average age was 53.6 14.69 years, and the mean
RMQ score at baseline was 8.68  4.90. The mean EQ-5D and SF-6D
utility scores for the BeST estimation sample at baseline were 0.56
 0.28 and 0.62  0.12, respectively. The UK BEAM validation
sample was signiﬁcantly younger and had signiﬁcantly higher
mean RMQ, EQ-5D utility, and SF-6D utility scores at baseline
compared with the BeST estimation sample, reﬂecting the differ-
ence in the inclusion criteria used by the studies.
Appendix Tables 1 and 2 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2014.07.001 present the summary
characteristics for the preference-based outcome measures in both
the estimation and validation samples across the different follow-
up points. There was variability in responses to individual levels of
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V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 8 6 – 6 9 5 689the EQ-5D dimensions and level 1 (“no problems”) did not always
have the highest proportion of responses. There was also a good
spread in responses to the SF-6D dimensions.
Figure 1 shows the distribution of the outcome measures in
both the estimation and validation samples. Broadly in keeping
with evidence found in other patient populations, the EQ-5D
utility scores are negatively skewed and bimodally distributed
[39]. The RMQ scores have a right skewed distribution, and the
SF-6D utility scores appear to be unimodal.
When using the GLM estimator for the EQ-5D data, the only
model that converged was the GLM with Gaussian family and
identity link, which is equivalent to the ordinary least squares
estimator and therefore the results are not reported. For the SF-
6D utility data, the GLM model selected as being best suited to the
data followed a gamma distribution and log link. Our reported
results for the mixture models assume three classes for EQ-5D
models and two classes for SF-6D models. We found that models
failed to converge when adding an additional class, with sub-
stantial overlap between coefﬁcients, and so we were unable to
make further estimations. The smooth functions in the general-
ized additive model were ﬁtted using splines.
The performance of all the models using preselected sets of
covariates was assessed using the estimation sample and, sepa-
rately, the validation sample.
Results of RMQ to EQ-5D Models
Appendix Table 3 in Supplemental Materials found at http://dx.
doi.org/10.1016/j.jval.2014.07.001 presents results showing sum-
mary performance indicators for all baseline and repeated obser-
vation RMQ to EQ-5D models for both the estimation and
validation samples. Focusing on the validation sample, the results
show that most of the baseline models accurately predicted the
mean EQ-5D utility score in the validation sample (0.63), with
predicted mean EQ-5D utility scores ranging from 0.60 to 0.66 (a
0.03 difference in utility score has been externally determined as
clinically important for evaluative purposes [40,41]). The excep-
tions were the ﬁrst CLAD model, the second beta regression QMLE
model, and all the beta regression maximum-likelihood estima-
tion models. A number of models were able to predict EQ-5D
utility scores into the negative range; the model predicting the
largest negative value closest to the actual one for the validation
sample was the second CLAD model (0.39).
In terms of repeated observation models, Appendix Table 3 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2014.07.001 presents that most of the models were able to fairly
accurately predict the mean EQ-5D utility score in the validation
sample (0.63), with predicted mean EQ-5D utility scores ranging
from 0.60 to 0.64. Of all the models, the MLOGIT robust cluster 3
model and mixture model 2 predicted the largest negative values
of 0.38 and 0.33, respectively.
Results of RMQ to SF-6D Models
Appendix Table 4 in Supplemental Materials found at http://dx.
doi.org/10.1016/j.jval.2014.07.001 presents summary performance
indicators for all baseline and repeated observation RMQ to SF-6D
models using both the estimation and validation samples. The
results show that the entire baseline RMQ to SF-6D models
accurately predicted the mean SF-6D utility score in the valida-
tion sample (0.66), with predicted mean SF-6D utility scores
ranging from 0.62 to 0.66. None of the models overpredicted the
highest SF-6D utility score.
In terms of repeated models, Appendix Table 4 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2014.07.001 presents
results showing that most of the models accurately predicted the
mean SF-6D utility score in the validation sample (0.66), with
Fig. 1 – Distribution of the outcome measures across the data sets at baseline. EQ-5D, EuroQol ﬁve-dimensional questionnaire;
RMQ, Roland Morris Questionnaire; SF-6D, six-dimensional health state short form (derived fromMedical Outcomes Study 36-
Item Short-Form Health Survey).
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of these models overpredicted the highest SF-6D utility score.Selection of Models
Models were initially selected on the basis of the Akaike infor-
mation criterion and then ﬁltered by removing those models thatwere strongly dominated, that is, performed worse in terms of
the MSE in both estimation and validation samples. The selection
process resulted in four algorithms being shortlisted for the RMQ
to EQ-5D mapping and eight models being shortlisted for the
RMQ to SF-6D mapping (models are presented in Table 2). Plots
comparing the mean errors in utility conditional on the RMQ
scores for the shortlisted models were also produced (see Fig. 2).
Table 2 – Model performance of shortlisted RMQ to EQ-5D and SF-6D models for the validation sample.
Model no. Mean  SD Min P.25 Median P.75 Max MSE MAE Absolute
difference
o0.10 (%)
Absolute
difference
o0.25 (%)
EQ-5D models
Actual EQ-5D 0.63  0.26 0.43 0.62 0.69 0.76 1.00
Direct mapping
Beta regression
QMLE 3*
0.63  0.17 0.11 0.55 0.67 0.76 0.84 0.0390 0.1410 51.67 83.55
Beta regression
QMLE 1
0.60  0.19 0.09 0.52 0.66 0.74 0.82 0.0395 0.1451 49.66 82.58
Beta regression
QMLE 3
0.61  0.17 0.16 0.52 0.66 0.74 0.81 0.0380 0.1416 51.59 83.05
Response mapping
MLOGIT robust
cluster 3
0.60  0.19 0.38 0.52 0.66 0.73 0.87 0.0397 0.1435 66.00 92.00
SF-6D models
Actual SF-6D 0.69  0.14 0.35 0.58 0.66 0.80 1.00
Direct mapping
Tobit 3* 0.64  0.08 0.37 0.60 0.66 0.70 0.78 0.0131 0.0905 70.00 97.00
Beta regression
QMLE 3*
0.65  0.08 0.40 0.59 0.66 0.71 0.80 0.0128 0.0906 62.27 97.72
Mixture model* 3 0.64  0.08 0.37 0.60 0.65 0.70 0.78 0.0132 0.0908 62.75 97.10
Tobit robust
cluster 3
0.66  0.09 0.40 0.60 0.67 0.73 0.80 0.0115 0.0860 75.00 99.00
Beta regression
QMLE 3
0.66  0.09 0.41 0.60 0.67 0.73 0.80 0.0115 0.0859 64.59 98.39
Mixture model 1 0.66  0.09 0.43 0.60 0.66 0.73 0.84 0.0114 0.0848 65.20 97.97
Mixture model 2 0.66  0.08 0.46 0.59 0.66 0.73 0.86 0.0114 0.0842 65.23 97.85
Response mapping
MLOGIT robust
cluster 3*
0.65  0.09 0.41 0.59 0.66 0.72 0.83 0.0117 0.0859 74.00 98.00
Note. Independent variables: model 1, RMQ score, age, and sex; model 2, RMQ score, RMQ score squared, age, age squared, sex, interaction term
for RMQ score and age; model 3, RMQ questions entered as categorical variables, age, and sex.
EQ-5D, EuroQol ﬁve-dimensional questionnaire; MAE, mean absolute error; MLE, maximum-likelihood estimation; MLOGIT, multinomial
logistic regression; MSE, mean squared error; QMLE, quasi-likelihood estimation; RMQ, Roland Morris Questionnaire; SF-6D, six-dimensional
health state short form (derived from Medical Outcomes Study 36-Item Short-Form Health Survey).
* Model is estimated using only baseline data.
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Table 2 contains the model performance results in the validation
sample for the shortlisted models. For each model, in addition to
assessing how accurately the models estimated the mean utility
scores, we examined the distributions of the predicted scores. Of
the RMQ to EQ-5D models, the MLOGIT robust cluster 3 model
based on repeated data gave the widest range of predicted utility
scores and the beta QMLE 3 model had the lowest MSE. All selected
models were able to predict negative values. Table 2 presents that
of the RMQ to SF-6D models, both mixture models had the smallest
MSE and the MLOGIT robust cluster 3 model based on baseline data
gave the widest range of predictions. Table 3 presents the MSE and
mean absolute error (MAE) values across the range of utility scores
for the selected models. Although the prediction accuracy for the
mean scores was similar across models, the level of accuracy was
not uniform across the full range of utility scores. If we ﬁrst look at
the RMQ to EQ-5D models, all models were better predictors toward
the upper end of the EQ-5D range. For EQ-5D utility scores between
0.5 and 0.8, the models had MSEs between 0.0129 and 0.0320,
whereas the MSE varied between 0.0254 and 0.1521 for predicted
values for the remaining range of scores. The results for the MAEs
followed a similar pattern to those for the MSEs. We now turn to the
results for the RMQ to SF-6D models. All models were able toaccurately predict across the whole range of SF-6D utility scores,
with MSEs between 0.0036 and 0.0499. The highest accuracy was
observed for SF-6D utility scores between 0.5 and 0.7.
Figure 2 shows plots comparing the mean errors in utility
conditional on the RMQ scores for the shortlisted models. Of the
RMQ to EQ-5D models, beta QMLE 3 based on baseline data and
beta QMLE 3 based on repeated data reported the lowest varia-
bility in errors across the RMQ scores and also had the lowest
error across RMQ scores. Of these two models, beta QMLE 3 based
on repeated data had the lowest MSE in the validation sample.
For the RMQ to SF-6D models, mixture models 1 and 2 based on
repeated data reported the lowest errors across the RMQ scores
and Tobit 3 based on baseline data and MLOGIT 3 based on
repeated data reported the lowest variability in errors across the
RMQ scores. Of these models, mixture model 2 had the lowest
MSE and MAE in the validation sample.
Based on these analyses, the preferred RMQ to EQ-5D model
was beta QMLE 3 based on repeated data and the model chosen
for mapping between RMQ and SF-6D was mixture model 2 based
on repeated data. We provide code for generating deterministic
and probabilistic utility predictions for these models, including
the coefﬁcients and their variance covariance matrices as sup-
plementary appendices.
Fig. 2 –Mean error in predicted utility score conditional on the RMQ score for shortlistedmodels. The top row contains the results for
the RMQ to EQ-5D models, and the bottom row contains the results for the RMQ to SF-6D models. EQ-5D, EuroQol ﬁve-dimensional
questionnaire; MLOGIT, multinomial logistic regression; QMLE, quasi-likelihood estimation; RMQ, Roland Morris Questionnaire; SF-
6D, six-dimensional health state short form (derived from Medical Outcomes Study 36-Item Short-Form Health Survey).
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We have developed a range of models that generate algorithms
for mapping between the RMQ and the EQ-5D and the SF-6D. The
performance of the shortlisted models in terms of overall MAE
was similar to that of previous mapping models, which have
obtained MAEs between 0.0011 and 0.19 [42]. The performance in
terms of the overall MSE was also within the range (0.0071 and
0.0400) of other reported mapping studies [42]. The selected
models were able to accurately predict mean utility scores in
the BeST and UK BEAM trial data sets, with more accurate
predictions observed at the upper end of the utility score ranges.
A recent literature review found that out of a total of 354 clinical
trials of chronic LBP, 132 used the RMQ as the functional outcome
measure, only 16 reported using the EQ-5D as a preference-basedoutcome measure, and only 4 made use of the SF-6D preference-
based outcome measure [43]. The mapping models provided in
supplementary appendices (in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2014.07.001) can be used to estimate
health utilities in situations in which only the RMQ has been
administered. The large ranges of ages and RMQ scores in our
samples give us greater conﬁdence in our extrapolations to other
study populations. Our study is, to our knowledge, the ﬁrst to estimate
associations between the RMQ and health utilities and, therefore, we
are not able to gauge our results with those of comparable studies.
This is also the ﬁrst study, to our knowledge, that uses response
mapping to predict responses to the SF-6D dimensions.
Utility data typically exhibit distributional properties such as
ceiling effects, skewed and at times multimodal distributions, and
nonlinear relationships with disease-speciﬁc measures, all of
which raise numerous statistical challenges. There has been a
Table 3 – Distribution of errors by observed EQ-5D and SF-6D range.
EQ-5D range *Beta
regression
QMLE 3
MLOGIT
robust
cluster 3
Beta
regression
QMLE 1
Beta
regression
QMLE 3
MSE MAE MSE MAE MSE MAE MSE MAE
o0 0.1515 0.3428 0.1372 0.3167 0.1571 0.3533 0.1521 0.3449
0–0.1 0.1370 0.3328 0.1287 0.3117 0.1380 0.3357 0.1370 0.3339
0.1–0.2 0.1309 0.3262 0.1273 0.3199 0.1280 0.3229 0.1305 0.3265
0.2–0.3 0.1431 0.3508 0.1392 0.3487 0.1379 0.3469 0.1409 0.3484
0.3–0.4 0.0470 0.1757 0.0503 0.1853 0.0464 0.1711 0.0465 0.1751
0.4–0.5 0.0405 0.1901 0.0403 0.1878 0.0303 0.1501 0.0393 0.1869
0.5–0.6 0.0296 0.1329 0.0364 0.1451 0.0320 0.1412 0.0286 0.1298
0.6–0.7 0.0223 0.1120 0.0269 0.1157 0.0237 0.1147 0.0218 0.1103
0.7–0.8 0.0129 0.0803 0.0145 0.0865 0.0142 0.0846 0.0130 0.0815
0.8–0.9 0.0254 0.0971 0.0324 0.106 0.0296 0.1086 0.0262 0.1057
0.9–1.0 0.0453 0.2067 0.0469 0.2087 0.0490 0.2145 0.0495 0.2170
SF-6D
range
Tobit 3 Beta regression
QMLE 3*
MLOGIT robust
cluster 3*
Mixture model 3* Tobit robust
cluster 3
Beta regression
QMLE 3
Mixture model 1 Mixture model 2
MSE MAE MSE MAE MSE MAE MSE MAE MSE MAE MSE MAE MSE MAE MSE MAE
0.35–0.5 0.0125 0.0914 0.0127 0.0891 0.0116 0.0888 0.0124 0.0913 0.0135 0.0926 0.0129 0.0901 0.0147 0.1026 0.0150 0.1040
0.5–0.6 0.0057 0.0603 0.0065 0.0648 0.005 0.0556 0.0057 0.0605 0.0068 0.0656 0.0067 0.0643 0.0059 0.0583 0.0057 0.0565
0.6–0.7 0.0036 0.0485 0.0046 0.0561 0.0037 0.0492 0.0036 0.0484 0.0048 0.0564 0.0050 0.0578 0.0051 0.0584 0.0058 0.0614
0.7–0.8 0.0095 0.0832 0.0085 0.0748 0.0109 0.0899 0.0088 0.0789 0.0074 0.0699 0.0071 0.0680 0.0076 0.0720 0.0083 0.0767
0.8–0.9 0.0283 0.1622 0.0259 0.1532 0.0306 0.1679 0.0284 0.1627 0.0226 0.1406 0.0226 0.1402 0.0231 0.1382 0.0229 0.1329
0.9–1.0 0.0484 0.2159 0.0414 0.1990 0.0499 0.2187 0.0464 0.2118 0.0364 0.1845 0.0338 0.1779 0.0316 0.1681 0.0287 0.1549
EQ-5D, EuroQol ﬁve-dimensional questionnaire; MAE, mean absolute error; MLOGIT, multinomial logistic regression; MSE, mean squared error; QMLE, quasi-likelihood estimation; SF-6D, six-
dimensional health state short form (derived from Medical Outcomes Study 36-Item Short-Form Health Survey).
* Model is estimated using only baseline data.
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V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 8 6 – 6 9 5694recent expansion in the methods that have been proposed to
analyze health utility data, but there are currently few examples
of mapping algorithms ﬁtted using these novel methods. A recent
review of studies mapping from quality-of-life or clinical meas-
ures to the EQ-5D [44] found that of the 90 selected studies only 2
made use of mixture models, and there were no mapping studies
as yet in which the beta regression or generalized additive models
had been used. A strength of our study is that we explore a wide
variety of statistical models, coupled with a range of inputs
(covariates) and outputs (direct and response mapping) in the
estimation of the mapping algorithms, to deal with these distri-
butional concerns. One limitation, however, is our use of ﬁnite
mixture models rather than adjusted limited dependent variable
mixture models [45] in the estimation of mapping algorithms for
the EQ-5D. The latter is generally preferred for EQ-5D data to allow
for the ceiling effect and gap between full health and next
possible EQ-5D utility value. Our data sets included a very small
number of individuals with full health, limiting the impact of not
using the adjusted limited dependent variable mixture models.
Other data sets used for the further reﬁnement of our algorithms,
however, may include larger numbers of respondents reporting
full health, in which case it would be inappropriate to use mixture
models without adjustment.
We found that beta regression models performed well with
both EQ-5D and SF-6D data and were not substantially outper-
formed by generalized additive models or mixture models, even
though the latter are potentially more ﬂexible in accommodating
nonlinear algorithms. It has been argued that beta distributions
are a ﬂexible choice for modeling health utilities [27], an argument
consistent with our ﬁndings for EQ-5D data. For SF-6D data, beta
and mixture regression models were comparably accurate, even
though the latter were marginally better. We cannot generalize
from these ﬁndings to make broad statements comparing recent
proposed approaches for the estimation of mapping algorithms,
but our study illustrates the potential beneﬁts of such approaches
and shows the importance of considering a wide range of
candidate regression models for constructing mappings.
The data sets we have contain repeated measurements over
several time points. All regression models were estimated using
only baseline data and reestimated using the repeated observa-
tions. The beneﬁt of repeated observations is that they can add
substantial information although not as much as independent
observations. Looking at out-of-sample prediction errors, we saw
clear beneﬁts from this extra information for all SF-6D utility
models as well as for EQ-5D utility models based on covariate set
3. However, the extra information did not yield such beneﬁts for
EQ-5D utility models based on sets 1 and 2. This may be because
models with covariate set 3 were more susceptible to overﬁtting
at the extremes of the dependent variables distribution, which
was reduced by the extra information. We explored two
approaches to using follow-up observations—multilevel models
and regression models with robust standard errors as have been
used in other studies [46–48]; these models assume that the same
algorithm applies across the different follow-up points. Further
work is underway looking at the implications of relaxing this
assumption and exploring the use of models of change in
response, which effectively model response levels as states and
attempt to predict the probability of transitions between levels at
successive follow-ups in terms of RMQ score changes over that
time. These transition response mappings should estimate how
predictable changes in EQ-5D or SF-6D responses are given
changes in RMQ scores, whereas other models have tended to
estimate the correlation between outcome measures at a ﬁxed
point in time. These different relationships may have independ-
ent causal factors or confounders. For example, at a given time,
factors other than back pain may inﬂuence anxiety or depression
levels, reducing the correlation between this response and theRMQ score. Furthermore, there is the potential of using
approaches such as Rasch analysis to explore whether particular
RMQ questions, singly or in combination, can be used to further
improve the prediction accuracy of our models.
We selected best-performing algorithms for EQ-5D and SF-6D
utilities using a multistage selection process involving multiple
criteria. Focusing on the “best” algorithm, however, fails to
account for structural uncertainty. This is particularly important
when models differ little in overall ﬁt but substantially in
predicted values where data are sparse. Further work is under-
way exploring the potential of applying a model-averaging
approach to our data, which would give a mapping algorithm
better-reﬂecting structural uncertainty.
This study has made use of regression techniques that are
widely used and accepted for mapping purposes and this facili-
tates the analysis and interpretation of the results. The mapping
models are validated on an external validation sample and the
fairly large sample sizes increase conﬁdence in the reliability of
our results. There are some caveats, however, that should be borne
in mind when interpreting our study results. First, the BeST study
made use of the SF-12(v2) whereas the SF-36(v2) was administered
in the UK BEAM trial. A possible strategy would have been to
estimate the SF-6D utilities for the BeST data using the SF-12
converter for the SF-6D and those for the UK BEAM data using the
SF-36 converter for the SF-6D. Using this approach it would not
have been possible to validate the response mapping models
because of the different number of response levels generated for
the SF-6D dimensions using the two alternative conversion algo-
rithms. Instead, we opted to extract responses to the 12 SF-12
questions from the SF-36 data contained in UK BEAM and calculate
SF-6D utilities using the SF-12 converter. This made it possible to
validate the response mapping models and also alleviated any
concerns surrounding the uncertainty introduced by the use of
different conversion algorithms. Second, the mapping models for
the EQ-5D in this study were based on the EQ-5D-3L; future work
will look at establishing the relationship between the RMQ and the
EQ-5D-5L once the valuation exercise for the latter measure has
been published. Third, all our estimations were based on complete
case analyses. This included more than 95% of individuals for the
baseline models, but only 78% for repeated observation models.
Selection bias is therefore a potential limitation for the latter
models. We found no evidence of such biases, however, when
comparing repeated and baseline models. Fourth, we had access to
only a single validation data set, so caution is required in using our
algorithms to predict utilities in populations that differ substan-
tially from those in our data sets. Further validation in additional
data sets with diverse populations would allow the identiﬁcation
of potential effect modiﬁers and the development of algorithms for
speciﬁc populations where required.
It will, of course, always be preferable to have preference- or
utility-based outcomes data collected as part of any evaluation of
treatment for LBP [9]. When this is not possible, however, the
results of our analyses show that it is possible to reasonably predict
utility scores from RMQ scores and responses using a regression
model framework. It is important to stress that if predicted utility
scores from mapping work are to be used to inform economic
evaluations, the uncertainty surrounding these predictions should
also be accounted for in the analyses. Nevertheless, our results can
be used to inform utility estimation within future economic
evaluations of interventions targeting LBP.Acknowledgments
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